← Back to Search

Behavioural Intervention

Gait analysis for Stroke (SENS-AG Trial)

N/A

Recruiting

Research Sponsored by REEV LLC

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Post-stroke gait disorder

Must be able to walk independently with or without the support of a cane or rollator

Timeline

Screening 3 weeks

Treatment Varies

Follow Up throughout study completion (an average of 2h)

Awards & highlights

SENS-AG Trial Summary

This trial is testing a new device called REEV SENSE, which is used to measure how people walk after having a stroke. The device will be compared to a standard method called motion capture. The

Who is the study for?

This trial is for individuals who have walking difficulties due to a stroke. Participants should be able to walk, even if assistance is needed. Specific details about who can join or reasons why someone might not be allowed to participate are not provided.Check my eligibility

What is being tested?

The study is testing the REEV SENSE gait tracker, which healthcare professionals use to measure how people walk after having a stroke. It's being compared with motion capture systems that are currently used.See study design

What are the potential side effects?

Since REEV SENSE involves non-invasive tracking of movement, side effects are likely minimal and may include discomfort from wearing the device or fatigue during gait assessment.

SENS-AG Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have walking difficulties after a stroke.

Select...

I can walk on my own, with or without a cane or walker.

Select...

I am 18 years old or older.

SENS-AG Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ throughout study completion (an average of 2h)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~throughout study completion (an average of 2h)

This trial's timeline: 3 weeks for screening, Varies for treatment, and throughout study completion (an average of 2h) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Walking speed measure precision

Secondary outcome measures

Ankle flexion angle measure precision in sagittal plan

KPP (Knee Position Predictor) measure precision = precision of the predicted angle of knee sagittal flexion in the next 200ms

Knee flexion angle measure precision in sagittal plan

+5 more

SENS-AG Trial Design

1Treatment groups

Experimental Treatment

Group I: Gait analysisExperimental Treatment2 Interventions

Gait analysis with the investigational and the reference devices

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

REEV LLCLead Sponsor

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any ongoing opportunities for patient enrollment in this clinical trial at the moment?

"Indeed, the information available on clinicaltrials.gov indicates that this particular clinical trial is actively seeking eligible participants. The initial posting of the study occurred on January 26th, 2024, and it was most recently updated on January 30th, 2024. The research team aims to recruit a total of 40 individuals from one specific location."

Answered by AI

How large is the overall participant pool in this medical study?

"Indeed, the information available on clinicaltrials.gov confirms that this trial is currently seeking participants. The initial posting for this clinical trial was made on January 26th, 2024 and the most recent update occurred on January 30th, 2024. In total, there are openings for 40 patients at a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

REEV SENSE for Gait Analysis in Post-stroke Gait Impairment (SENS-AG)

2024. "REEV SENSE for Gait Analysis in Post-stroke Gait Impairment (SENS-AG)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06234878.

All > Autonomic Dysfunction > Paid Studies Boston